Stability and sterility of recombinant tissue plasminogen activator at −30°C

doi:10.1016/S0140-6736(00)02411-9

The Lancet

Volume 355, Issue 9222, 24 June 2000, Page 2221

https://doi.org/10.1016/S0140-6736(00)02411-9 Get rights and content

Summary

We assessed whether frozen recombinant tissue plasminogen activator (rt-PA) remains stable and sterile for up to 22 weeks at −30°C. Our findings confirm that rt-PA is a cost-effective alternative to urokinase for restoring patency to occluded central venous catheters.

References (3)

JA Cairns et al.
Coron Thrombolysis Chest
(1998)

There are more references available in the full text version of this article.

Cited by (20)

Thromboembolic complications in children with cancer
2006, Thrombosis Research
Thrombosis is a significant problem in patients with cancer. The impact of thromboembolism in association with childhood cancer is not clearly defined. Similarly the information of prevention and management of thromboembolic events in children receiving cancer-therapy is limited. This review aims to examine current knowledge regarding the epidemiology, pathophysiology and management of thrombosis in association with cancer in children.
Alteplase and tenecteplase: Applications in the peripheral circulation
2001, Techniques in Vascular and Interventional Radiology
Alteplase (t-PA), a recombinant analogue of human tissue plasminogen activator, became the first genetically engineered thrombolytic approved by the Food and Drug Administration in 1987 for acute myocardial infarction (AMI). In addition to AMI, alteplase is currently approved for the treatment of acute ischemic stroke and pulmonary embolism, and we anticipate approval for catheter clearance in late 2001 in a 2-mg vial configuration. With the withdrawal of human neonatal kidney cellderived urokinase, alteplase has become an alternative agent in peripheral vascular applications. Because few interventionalists had prior experience with the handling and dosage of alteplase, the Advisory Panel to the Soceity of Cardiovascular and Interventional Radiology established practice guidelines for use in noncoronary applications. Emerging clinical experience with contemporary dosing regimens shows a safety and efficacy profile similar to urokinase but with significantly reduced drug costs. Tenecteplase (TNK) is a genetically modified version of alteplase. TNK is the only plasminogen activator available that has shown a significantly enhanced safety profile versus alteplase in AMI. Approved for a 5-second, single-bolus injection in AMI, TNK possesses a longer half-life, increased resistance to plasminogen activator inhibitor, and improved fibrin specificity compared with alteplase. Because of its enhanced safety profile, TNK may be a desirable agent for peripheral vascular applications. Initial clinical studies with TNK in acute arterial and venous disease are ongoing. This article outlines the Advisory Panel guidelines for using alteplase and highlights features of tenecteplase.
The use of alteplase to restore patenqy of central venous lines in pediatric patients: A cohort study
2001, Journal of Pediatrics
Citation Excerpt :
In one case series including 5 children, alteplase was successful in 5 of 6 patients at re-establishing patency after UK had failed in all patients.6 The cost effectiveness of alteplase compared with that of other urokinase agents has also been demonstrated.21 The type of CVL did not appear to affect the efficacy or safety of the treatment; however, the distribution of CVL types in our study may not be typical among pediatric centers.
We evaluated the efficacy and safety of alteplase to restore central venous line (CVL) patency in a consecutive cohort study. A uniform, weight-dependent protocol for alteplase administration was established prospectively. For children ≤10 kg, a dose of 0.5 mg was used; for children >10 kg, doses of 1 to 2 mg were used. The alteplase remained instilled for 1 to 4 hours or overnight. Retrospective data accrual found that 25 children received alteplase for a total of 34 courses; 29 (85%) of the 34 courses of alteplase completely restored CVL patency. Alteplase appears to be a safe and effective thrombolytic agent for CVL patency restoration in children. (J Pediatr 2001;139:152-6)
Efficacy of alteplase 1 versus 2 mg dose in restoring haemodialysis catheter function (Alte-dose 2): A randomized double-blind controlled study
2020, Nephrology
Spectrophotometric analysis of thrombolytic activity: SATA assay
2018, BioImpacts
Stability of recombinant tissue plasminogen activator at -30 °c over one year
2013, Pharmaceuticals

View all citing articles on Scopus

View full text

Research LettersStability and sterility of recombinant tissue plasminogen activator at −30°C

Summary

Coron Thrombolysis Chest

Research Letters
Stability and sterility of recombinant tissue plasminogen activator at −30°C